Abstract: A method of treating patients suffering from carcinoma of intrahepatic or extra hepatic bile duct or gall bladder which is locally advanced or metastatic, by intravenously administering to the patient, paclitaxel in the form of a nanodispersion. The nanodispersion comprises particles with a mean particle size less than 300 nm and is free of polyoxyethylated castor oil and free of a protein.

Abstract: The present invention provides a sustained release microsphere composition comprising (i) microspheres comprising (A) a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 to about 3:1, and (B) a therapeutically effective amount of goserelin or a pharmaceutically acceptable salt thereof, and (ii) pharmaceutically acceptable excipients, which when injected intramuscularly, delivers goserelin or a pharmaceutically acceptable salt thereof, for a period of at least one month.

Abstract: A sustained release microsphere composition comprising— (i) microspheres comprising (A) a biodegradable polymer which is a homopolymer of lactic acid or a copolymer of lactic acid and glycolic acid having a monomer ratio in the range of about 1:1 to about 3:1, and (B) a therapeutically effective amount of octreotide acetate, and (ii) pharmaceutically acceptable excipients, which when injected, delivers octreotide acetate, for a period of at least one month.

Abstract: A process for the manufacture of free-flowing uniformly sized micro spheres for the sustained release of therapeutically active ingredient comprising: a) preparing a first dispersed phase comprising a therapeutically active ingredient, a biodegradable polymer and an organic solvent; b) mixing the first dispersed phase with a aqueous phase to form an emulsion; c) spraying the emulsion into a vessel (20) equipped with organic solvent removal means; d) passing the suspension of micro spheres through screens and collecting a fractionated size of the microspheres on the surface of the screens; e) drying the microspheres wherein steps a to e are carried out without manual intervention, in equipment connected in series, substantially unexposed to the environment;

Abstract: A nicardipine hydrochloride injection composition comprising sorbitol in amounts sufficient to stabilize the injection preparation and a physiologically and pharmaceutically acceptable buffer, in an amount effective to maintain the pH of the composition at about 3.0 to about 4.5.